135 related articles for article (PubMed ID: 20664355)
1. A pilot study of denileukin diftitox (DD) in combination with high-dose interleukin-2 (IL-2) for patients with metastatic renal cell carcinoma (RCC).
Atchison E; Eklund J; Martone B; Wang L; Gidron A; Macvicar G; Rademaker A; Goolsby C; Marszalek L; Kozlowski J; Smith N; Kuzel TM
J Immunother; 2010 Sep; 33(7):716-22. PubMed ID: 20664355
[TBL] [Abstract][Full Text] [Related]
2. Phase II clinical studies of denileukin diftitox diphtheria toxin fusion protein in patients with previously treated chronic lymphocytic leukemia.
Frankel AE; Surendranathan A; Black JH; White A; Ganjoo K; Cripe LD
Cancer; 2006 May; 106(10):2158-64. PubMed ID: 16586495
[TBL] [Abstract][Full Text] [Related]
3. Increase of circulating CD4+CD25highFoxp3+ regulatory T cells in patients with metastatic renal cell carcinoma during treatment with dendritic cell vaccination and low-dose interleukin-2.
Berntsen A; Brimnes MK; thor Straten P; Svane IM
J Immunother; 2010 May; 33(4):425-34. PubMed ID: 20386464
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma.
Dang NH; Hagemeister FB; Pro B; McLaughlin P; Romaguera JE; Jones D; Samuels B; Samaniego F; Younes A; Wang M; Goy A; Rodriguez MA; Walker PL; Arredondo Y; Tong AT; Fayad L
J Clin Oncol; 2004 Oct; 22(20):4095-102. PubMed ID: 15353540
[TBL] [Abstract][Full Text] [Related]
6. [Effect of transcatheter renal arterial embolization combined with cryoablation on regulatory CD4+ CD25+ T lymphocytes in the peripheral blood of patients with advanced renal carcinoma].
Liu CF; Guo Z; Si TG; Xing WG; Liu F; Xing JZ
Zhonghua Yi Xue Za Zhi; 2010 Apr; 90(13):902-5. PubMed ID: 20646510
[TBL] [Abstract][Full Text] [Related]
7. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma.
Prince HM; Duvic M; Martin A; Sterry W; Assaf C; Sun Y; Straus D; Acosta M; Negro-Vilar A
J Clin Oncol; 2010 Apr; 28(11):1870-7. PubMed ID: 20212249
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells.
Dannull J; Su Z; Rizzieri D; Yang BK; Coleman D; Yancey D; Zhang A; Dahm P; Chao N; Gilboa E; Vieweg J
J Clin Invest; 2005 Dec; 115(12):3623-33. PubMed ID: 16308572
[TBL] [Abstract][Full Text] [Related]
9. A phase I trial of CD3/CD28-activated T cells (Xcellerated T cells) and interleukin-2 in patients with metastatic renal cell carcinoma.
Thompson JA; Figlin RA; Sifri-Steele C; Berenson RJ; Frohlich MW
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3562-70. PubMed ID: 14506142
[TBL] [Abstract][Full Text] [Related]
10. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma.
Attia P; Maker AV; Haworth LR; Rogers-Freezer L; Rosenberg SA
J Immunother; 2005; 28(6):582-92. PubMed ID: 16224276
[TBL] [Abstract][Full Text] [Related]
11. Ten-year survival results in metastatic renal cell cancer patients treated with monoimmunotherapy with subcutaneous low-dose interleukin-2.
Lissoni P; Bordin V; Vaghi M; Fumagalli L; Bordoni A; Mengo S; Bucovec R; Fumagalli E; Malugani F; Ardizzoia A; Giani L; Gardani GS; Tancini G
Anticancer Res; 2002; 22(2B):1061-4. PubMed ID: 12168901
[TBL] [Abstract][Full Text] [Related]
12. Pilot study of denileukin diftitox alternate dosing regimen in patients with cutaneous peripheral T-cell lymphomas.
Talpur R; Duvic M
Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):180-5. PubMed ID: 22521504
[TBL] [Abstract][Full Text] [Related]
13. Correlation of clinical and immunological parameters of metastatic renal cell carcinoma patients undergoing therapy with interleukin 2, interferon-alpha and retinoic acid.
Elsässer-Beile U; Kölble N; Grussenmeyer T; Wetterauer U; Schultze-Seemann W
Anticancer Res; 1998; 18(3B):1883-90. PubMed ID: 9677439
[TBL] [Abstract][Full Text] [Related]
14. Duration of response in cutaneous T-cell lymphoma patients treated with denileukin diftitox: results from 3 phase III studies.
Duvic M; Geskin L; Prince HM
Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):377-84. PubMed ID: 23770157
[TBL] [Abstract][Full Text] [Related]
15. Upfront denileukin diftitox as in vivo regulatory T-cell depletion in order to enhance vaccination effects in a canine allogeneic hematopoietic stem cell transplantation model.
Knueppel A; Lange S; Altmann S; Sekora A; Knuebel G; Vogel H; Lindner I; Freund M; Junghanss C
Vet Immunol Immunopathol; 2012 Jan; 145(1-2):233-40. PubMed ID: 22173275
[TBL] [Abstract][Full Text] [Related]
16. Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer.
van der Vliet HJ; Koon HB; Yue SC; Uzunparmak B; Seery V; Gavin MA; Rudensky AY; Atkins MB; Balk SP; Exley MA
Clin Cancer Res; 2007 Apr; 13(7):2100-8. PubMed ID: 17404092
[TBL] [Abstract][Full Text] [Related]
17. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.
Kato Y; Yoshimura K; Shin T; Verheul H; Hammers H; Sanni TB; Salumbides BC; Van Erp K; Schulick R; Pili R
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4538-46. PubMed ID: 17671140
[TBL] [Abstract][Full Text] [Related]
18. Standard interleukin-2 (IL-2) and interferon-alpha immunotherapy versus an IL-2 and 4-epirubicin immuno-chemotherapeutic association in metastatic renal cell carcinoma.
Naglieri E; Gebbia V; Durini E; Lelli G; Abbate I; Selvaggi FP; Di Tonno P; Colucci G
Anticancer Res; 1998; 18(3B):2021-6. PubMed ID: 9677460
[TBL] [Abstract][Full Text] [Related]
19. Effect of transcatheter renal arterial embolization combined with cryoablation on regulatory CD4+CD25+ T lymphocytes in the peripheral blood of patients with advanced renal carcinoma.
Li Y; Guo Z; Liu CF; Xing WG; Si TG; Liu F; Guo XY; Xing JZ
Cryobiology; 2012 Aug; 65(1):56-9. PubMed ID: 22521783
[TBL] [Abstract][Full Text] [Related]
20. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
